| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Adagio Medical Holdings, Inc. | Director | Non-qualified stock option (right to buy) | 90,000 | 20 Mar 2025 | Direct | ||
| Lucira Health, Inc. | Director | Stock Option (right to buy) | 59,459 | 01 Jun 2022 | Direct | ||
| Pulse Biosciences, Inc. | CFO & EVP Admin. and Finance | Stock Option (right to buy) | 51,922 | 14 Dec 2021 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| ADGM | Adagio Medical Holdings, Inc. | 20 Mar 2025 | 1 | $0 | 4 | Director | 21 Mar 2025, 18:59 |
| ADGM | Aja Holdco, Inc. | 31 Jul 2024 | 0 | $0 | 3 | Director | 01 Aug 2024, 17:07 |
| KRON | Kronos Bio, Inc. | 15 Sep 2023 | 0 | $0 | 3 | Interim CFO | 18 Sep 2023, 16:54 |
| NKTR | NEKTAR THERAPEUTICS | 17 Apr 2023 | 0 | $0 | 3 | Chief Financial Officer | 25 Apr 2023, 21:03 |
| ANEB | Anebulo Pharmaceuticals, Inc. | 02 Mar 2023 | 0 | $0 | 3 | Acting Chief Financial Officer | 04 Apr 2023, 18:32 |
| /report/000120919122034078-gardiner-sandra-a-2022-06-01 | Lucira Health, Inc. | 01 Jun 2022 | 1 | $0 | 4 | Director | 03 Jun 2022, 16:36 |
| PLSE | Pulse Biosciences, Inc. | 14 Dec 2021 | 1 | $0 | 4 | CFO & EVP Admin. and Finance | 28 Feb 2022, 12:42 |